Wednesday, April 11, 2012 7:03:16 AM
Pharming Redeems Fourth Tranche Of Convertible Bond
Leiden, The Netherlands, April 11, 2012. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) today announced that it has redeemed the fourth tranche of its €8.4 million convertible bond. A total of 22,051,282 shares were issued to the bondholders under the terms and conditions of the bond, serving as a pre-installment for the May 15, 2012 redemption and interest payment.
As announced in our press release on December 23, 2011, Pharming will redeem the bond on a month by month basis in six equal monthly tranches of €1.4 million and the interest payable, such that the bond will be redeemed in full on July 15, 2012. Pharming can decide at its discretion to redeem the bond and pay the interest due, by means of monthly equity tranches or cash payments.
As of today, the number of outstanding shares has increased from 561,503,681 to 583,554,963.
Leiden, The Netherlands, April 11, 2012. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) today announced that it has redeemed the fourth tranche of its €8.4 million convertible bond. A total of 22,051,282 shares were issued to the bondholders under the terms and conditions of the bond, serving as a pre-installment for the May 15, 2012 redemption and interest payment.
As announced in our press release on December 23, 2011, Pharming will redeem the bond on a month by month basis in six equal monthly tranches of €1.4 million and the interest payable, such that the bond will be redeemed in full on July 15, 2012. Pharming can decide at its discretion to redeem the bond and pay the interest due, by means of monthly equity tranches or cash payments.
As of today, the number of outstanding shares has increased from 561,503,681 to 583,554,963.
Recent PHARM News
- European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union • GlobeNewswire Inc. • 05/22/2026 07:30:00 PM
- Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders • GlobeNewswire Inc. • 05/07/2026 05:05:00 AM
- Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 • GlobeNewswire Inc. • 05/07/2026 05:00:00 AM
- Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older • GlobeNewswire Inc. • 03/27/2026 06:00:00 AM
- Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older • GlobeNewswire Inc. • 03/24/2026 06:00:00 AM
- Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow • GlobeNewswire Inc. • 03/12/2026 06:00:00 AM
- Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day • GlobeNewswire Inc. • 02/03/2026 06:00:00 AM
- Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS • GlobeNewswire Inc. • 02/01/2026 08:17:00 PM
- DAX, CAC, FTSE100, European equities drift lower amid U.S.–Venezuela tensions and data watch • UK Market News • 01/08/2026 02:17:15 PM
- Pharming Group reports preliminary 2025 revenues and announces Investor Day • GlobeNewswire Inc. • 01/08/2026 06:00:00 AM
- Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow • GlobeNewswire Inc. • 11/06/2025 06:00:00 AM
- Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio • GlobeNewswire Inc. • 10/20/2025 06:00:33 AM
- Pharming Group provides update on previously announced G&A expense reduction plan • GlobeNewswire Inc. • 10/06/2025 03:35:57 PM
- Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years • GlobeNewswire Inc. • 10/01/2025 05:00:25 AM
- Pharming Group promoted to the Euronext AMX® index • GlobeNewswire Inc. • 09/10/2025 05:00:00 AM
- Pharming Group appoints Kenneth Lynard as Chief Financial Officer • GlobeNewswire Inc. • 09/02/2025 05:00:00 AM
- Pharming Group reports second quarter and first half 2025 financial results and provides business update • GlobeNewswire Inc. • 07/31/2025 05:00:00 AM
- Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis • GlobeNewswire Inc. • 06/24/2025 05:00:00 AM
